Accuray Incorporated (NASDAQ: ARAY) announced today the company has received CE Mark for Accuray Helix™, a CT-guided helical radiotherapy system designed to provide high-performance and high-throughput.
The new system is intended for emerging markets where access to advanced cancer care, including radiotherapy treatments, is typically obtainable only within urban areas and where the availability of linear accelerators per million population is well below the World Health Organization recommended guidelines. Accuray Helix offers a solution for clinical teams that require short treatment times and cost effectiveness to establish a care path for patients in non-urban communities who previously had limited options.
Radiotherapy is a fundamental component of cancer care1 and can be used in the treatment of localized disease, recurrent or metastatic cancer. An estimated 50 percent of people with cancer would benefit from radiation therapy2 either as their sole care option or along with other modalities such as surgery, chemotherapy or immunotherapy.
“While the demand for cancer services is increasing globally, there are certain areas of the world where there continues to be greater gaps in access to radiation medicine. India is a priority due to this disparity as there is a significant deficit in availability of radiation therapy systems compared to the size if its population and incidence of cancer. Our goal with the introduction of Accuray Helix is to close some of these gaps to patient access with our comprehensive solutions,” said Suzanne Winter, president and CEO of Accuray. “The Accuray Helix system combines affordability with automation and tools for enhancing the speed of planning and delivery of radiation. We believe it will enable a broader range of capabilities for facilities that may have resources and staffing for only one system, enabling them to offer state-of-the-art cancer care in their communities.”
Accuray Helix delivers precise, targeted radiation treatments, an important option for the routine cases clinical teams see daily in their practice including breast, cervix, head and neck, gastrointestinal, lung, and prostate. The system’s flexibility and versatility are intended to drive improvements in personalization and patient care, while simultaneously facilitating the treatment of more patients each day, boosting productivity for clinics and enabling them to efficiently manage the growing demand for cancer care.
Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.